Aha BOOST Arm-hand BOOST Therapy to Enhance Recovery After Stroke: Clinical, Health Economic and Process Evaluation
Launched by KU LEUVEN · Jul 18, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new therapy called arm-hand BOOST to see if it can help people recover better after having a stroke. The aim is to find out if this therapy, when added to the usual care, can improve the use of the arm and hand, increase independence, and enhance overall quality of life for patients in the weeks following their stroke. The study will involve 80 patients who are within five months of experiencing their first stroke. To participate, individuals must be at least 18 years old, have some movement difficulties in their arm, and be able to sit up independently.
Participants in the study will be randomly assigned to either the arm-hand BOOST therapy group or a control group receiving a different form of therapy focused on leg exercises. The arm-hand BOOST program includes group exercises and technology-supported therapy for one hour a day, five days a week, for four weeks. Throughout the study, researchers will assess how well the therapies work by looking at improvements in arm and hand function, overall independence, and quality of life at several points, including after the therapy and one year later. Additionally, the study will gather information about the costs associated with these therapies to see if the investment in this extra treatment is worthwhile.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Maximally 5 months after a first-ever unilateral, supra-tentorial stroke
- • Minimally 18 years old
- • A residual inpatient stay of minimally 4 weeks
- • The ability to sit independently
- • Motor impairment in the upper limb, as defined, based on the JSU diagram, as a score of 8-17 on stage 2 (synergies) of the Fugl-Meyer assessment upper extremity (FMA-UE) or a score of \<8 on stage 2 of the FMA-UE, combined with a score of \>6 on stage 5 (hand) of the FMA-UE.
- Exclusion Criteria:
- • Severe communication deficits as defined as a score of \<24 out of 32 on the 'visual sentence comprehension' subscale of the Comprehensive Aphasia Test.
- • Severe cognitive deficits as defined as a score of \<18 out of 30 on the Montreal Cognitive Assessment.
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, Antwerpen, Belgium
Gent, Oost Vlaanderen, Belgium
Patients applied
Trial Officials
Verheyden Geert, Professor
Principal Investigator
KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported